Updated:
Axim Biotechnologies
Axim Biotechnologies, Inc. was incorporated in the United States with a strategic orientation toward the life sciences sector.
Axim Biotechnologies
Axim Biotechnologies, Inc. was incorporated in the United States with a strategic orientation toward the life sciences sector. The firm's founding capital originated from the biotech industry, though specific principals or wealth origin details remain undisclosed in public records. The firm's investment strategy spans biotechnology and pharmaceutical asset classes, with a focus on therapeutic areas including cannabinoid-based medicines and other novel drug candidates. Axim typically targets early-stage through clinical-stage companies, employing direct investments and co-investment structures alongside other healthcare-focused investors. Geographic exposure is concentrated in North America. Axim operates with a lean team structure, and no additional office locations or adjacent philanthropic vehicles have been publicly identified. The firm has not disclosed recent operational events within the last 24 months. Axim's structural differentiator lies in its concentration on a narrow therapeutic niche—cannabinoid-based pharmaceuticals—an area that requires specialized regulatory and scientific diligence. This focus distinguishes it from broader healthcare family offices.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
United States
Sector focus
Frequently asked questions
Who manages investment decisions at Axim Biotechnologies?
The specific investment managers or principals of Axim Biotechnologies are not publicly identified. The firm does not publicly disclose its team composition, but as a family office, investment decisions are likely made by a small group of principals or external advisors.
What therapeutic areas does Axim Biotechnologies focus on?
Axim Biotechnologies concentrates on cannabinoid-based pharmaceuticals and other novel drug candidates addressing unmet medical needs. Its portfolio historically includes compounds targeting conditions such as pain, inflammation, and neurological disorders.
Does Axim Biotechnologies invest through funds or direct deals?
Based on public filings and corporate structure, Axim typically makes direct investments and may participate in co-investment opportunities. The firm does not appear to operate a fund-of-funds model.
What investment stages does Axim Biotechnologies target?
Axim Biotechnologies generally targets early-stage to clinical-stage biotechnology companies. This includes companies at preclinical development through Phase II clinical trials.
Where does the underlying wealth for Axim Biotechnologies come from?
The wealth origin is tied to the biotechnology and pharmaceutical sectors, but specific family sources are not publicly disclosed. The firm's name suggests a connection to the biotech industry.
Is Axim Biotechnologies structured as a single-family office?
Yes, Axim Biotechnologies is structured as a single-family office, based on its corporate filings and investment behavior. It does not serve external clients or manage third-party capital.
What geographic markets does Axim Biotechnologies focus on?
Axim Biotechnologies primarily invests in North American companies, with a particular focus on the United States. No international offices or foreign investments have been publicly reported.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: